Rufinamide in Children with Refractory Epilepsy: Pharmacokinetics, Efficacy, and Safety

Abstract

We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of RUF and concomitant AEDs were calculated: the weight-normalized dose (mg/kg/d) divided by the steady-state trough plasma drug level, which was used as a measure of clearance. During treatment with RUF concomitantly with valproic acid (VPA) young children, aged 0 to 4.9 years, had a low clearance of RUF, which did not differ from older children. If not on VPA but on enzyme inducers, young children had a threefold higher clearance of RUF than the older ones. In young children not on VPA, those on enzyme inducers had 1.7-fold higher clearance than those on nonenzyme inducers. In children neither on VPA nor on enzyme inducers, RUF clearance was age-dependent with higher clearance in younger children. Adding RUF did not change the pharmacokinetics of concomitantly used AEDs. Seizure response after 2 to 3 months on RUF treatment was found in 12 of 51 children (23.5%), at mean plasma level of 36.9 ± 22.0 µmol/L. Adverse events were reported in 41% of the patients of which fatigue was most frequent (24%).

Keywords

rufinamide - plasma level - dose-to-concentration ratio - clearance - child - age - VPA - enzyme inducer

• References

• 1 Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70 (21) 1950-1958
• 2 Coppola G, Grosso S, Franzoni E , et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Seizure 2010; 19 (9) 587-591
• 3 Kluger G, Kurlemann G, Haberlandt E , et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009; 14 (3) 491-495
• 4 Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49 (7) 1123-1141
• 5 Ferrie CD. Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome. Expert Rev Neurother 2010; 10 (6) 851-860
• 6 Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome. Ann Pharmacother 2010; 44 (4) 658-667
• 7 May TW, Boor R, Rambeck B, Jürgens U, Korn-Merker E, Brandt C. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2011; 33 (2) 214-221
• 8 Deeks ED, Scott LJ. Rufinamide. CNS Drugs 2006; 20 (9) 751-760 , discussion 761
• 9 Wheless JW, Conry J, Krauss G, Mann A, LoPresti A, Narurkar M. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24 (12) 1520-1525
• 10 Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010; 10 (1) 1-6
• 11 Brodie MJ, Rosenfeld WE, Vazquez B , et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009; 50 (8) 1899-1909
• 12 Elger CE, Stefan H, Mann A, Narurkar M, Sun Y, Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010; 88 (2-3) 255-263
• 13 Joseph JR, Schultz RJ, Wilfong AA. Rufinamide for refractory epilepsy in a pediatric and young adult population. Epilepsy Res 2011; 93 (1) 87-89
• 14 Vendrame M, Loddenkemper T, Gooty VD , et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol 2010; 43 (3) 155-158